CSPC PHARMA (01093) rose more than 5%. As of the time of writing, the stock was up 5.14%, trading at HK$10.44, with a turnover of HK$499 million. According to an announcement on CSPC Pharma's official WeChat account, the results of a Phase III clinical study for Anituzumab (KN026), co-developed by CSPC Pharma and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., targeting patients with HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma, have been successfully published in the top-tier oncology journal Annals of Oncology (Impact Factor: 65.4). This study was a randomized, double-blind, controlled, multi-center Phase III clinical trial designed to evaluate the efficacy and safety of Anituzumab combined with chemotherapy compared to standard treatment in HER2-positive gastric cancer/gastroesophageal junction adenocarcinoma patients who had previously failed first-line treatment containing trastuzumab.